Top
Summary
All studies
Mortality
Ventilation
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
All proxalutamide studies
 
Feedback
Home
c19early.org COVID-19 treatment researchProxalutamideProxalutamide (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

Outcomes in COVID-19 proxalutamide studies

0 0.5 1 1.5+ All studies 78% 4 1,953 Improvement, Studies, Patients Relative Risk Mortality 78% 4 1,953 Ventilation 95% 2 445 Hospitalization 72% 4 1,953 Viral clearance 74% 1 0 RCTs 78% 4 1,953 RCT mortality 78% 4 1,953 Peer-reviewed 78% 2 1,046 Early 71% 3 1,175 Late 78% 1 778 Proxalutamide for COVID-19 c19early.org Sep 2023 Favorsproxalutamide Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% lower risk Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% lower risk All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% lower risk 4 proxalutamide COVID-19 studies c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] 0/365 1/365 Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% lower risk Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% lower risk All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% lower risk 4 proxalutamide COVID-19 mortality results c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 97% 0.03 [0.00-0.47] 0/134 17/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] 0/75 5/102 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0043 Early treatment 95% 0.05 [0.01-0.40] 0/209 22/236 95% lower risk All studies 95% 0.05 [0.01-0.40] 0/209 22/236 95% lower risk 2 proxalutamide COVID-19 mechanical ventilation results c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0043 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Kintor (DB RCT) 50% 0.50 [0.15-1.65] hosp. 4/365 8/365 Tau​2 = 0.47, I​2 = 53.4%, p = 0.002 Early treatment 81% 0.19 [0.07-0.54] 9/574 62/601 81% lower risk Cadegiani (DB RCT) 33% 0.67 [0.54-0.82] hosp. time 423 (n) 355 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0001 Late treatment 33% 0.67 [0.54-0.82] 0/423 0/355 33% lower risk All studies 72% 0.28 [0.10-0.81] 9/997 62/956 72% lower risk 4 proxalutamide COVID-19 hospitalization results c19early.org Sep 2023 Tau​2 = 0.87, I​2 = 80.5%, p = 0.019 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% lower risk Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% lower risk All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% lower risk 4 proxalutamide COVID-19 serious outcomes c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani (DB RCT) 45% 0.55 [0.49-0.62] no recov. 423 (n) 355 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 45% 0.55 [0.49-0.62] 0/423 0/355 45% lower risk All studies 45% 0.55 [0.49-0.62] 0/423 0/355 45% lower risk 1 proxalutamide COVID-19 recovery result c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kintor (DB RCT) 74% 0.26 [0.13-0.51] viral+ n/a n/a Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Early treatment 74% 0.26 [0.13-0.51] 74% lower risk All studies 74% 0.26 [0.13-0.51] 74% lower risk 1 proxalutamide COVID-19 viral clearance result c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% lower risk Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% lower risk All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% lower risk 4 proxalutamide COVID-19 Randomized Controlled Trials c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] 0/365 1/365 Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% lower risk Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% lower risk All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% lower risk 4 proxalutamide COVID-19 RCT mortality results c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.3 Early treatment 80% 0.20 [0.01-4.13] 0/134 2/134 80% lower risk Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% lower risk All studies 78% 0.22 [0.16-0.30] 45/557 173/489 78% lower risk 2 proxalutamide COVID-19 peer reviewed studies c19early.org Sep 2023 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 censored, see notes Improvement, RR [CI] Treatment Control McCoy (DB RCT) 97% 0.03 [0.00-0.47] ventilation 0/134 17/134 censored, see notes McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 censored, see notes Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] ventilation 0/75 5/102 Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Kintor (DB RCT) 50% 0.50 [0.15-1.65] hosp. 4/365 8/365 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/360 1/361 Kintor (DB RCT) 71% 0.29 [0.06-1.37] hosp. 2/360 7/361 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/346 1/347 Kintor (DB RCT) 92% 0.08 [0.01-0.79] hosp. 0/346 6/347 Kintor (DB RCT) 74% 0.26 [0.13-0.51] viral+ n/a n/a Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Cadegiani (DB RCT) 79% 0.21 [0.15-0.30] death 34/423 138/355 Cadegiani (DB RCT) 45% 0.55 [0.49-0.62] no recov. 423 (n) 355 (n) Cadegiani (DB RCT) 55% 0.45 [0.39-0.52] no recov. 423 (n) 355 (n) Cadegiani (DB RCT) 33% 0.67 [0.54-0.82] hosp. time 423 (n) 355 (n) Proxalutamide COVID-19 outcomes c19early.org Sep 2023 Favors proxalutamide Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit